XERS
Xeris Biopharma Holdings, Inc.Company Information
- Company Name
- Xeris Biopharma Holdings, Inc.
- CIK
- CIK0001867096
- Category
- Large accelerated filer
- Ticker: Exchange
- XERS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- XERS
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-06-13
- Last sale
- 2026-09-28
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 656,817
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 108,553,147
- Shares outstanding
- 172,823,455
- Ownership
- 62.81%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 15.22%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 122 | 112 | 111 | 92 | 59 | 58 | 72 | 59 | 58 | 72 | 67 | 46 | ||||||
| Accounts Receivable Net Current | 58 | 56 | 51 | 54 | 53 | 46 | 40 | 41 | 42 | 40 | 39 | 46 | ||||||
| Inventory Net | 81 | 74 | 69 | 67 | 67 | 53 | 48 | 45 | 43 | 48 | 39 | 38 | ||||||
| Short Term Investments | - | - | - | - | - | - | 0 | 10 | 20 | 0 | 5 | 20 | ||||||
| Prepaid Expense Current | 14 | 9 | 10 | 11 | 6 | 6 | 7 | 7 | 7 | 7 | 6 | 8 | ||||||
| Assets Current | 275 | 252 | 240 | 224 | 186 | 163 | 168 | 163 | 170 | 168 | 156 | 158 | ||||||
| Property Plant And Equipment Net | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | ||||||
| Operating Lease Right Of Use Asset | 22 | 22 | 22 | 22 | 22 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | ||||||
| Goodwill | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | ||||||
| Intangible Assets Net Excluding Goodwill | 83 | 85 | 88 | 91 | 94 | 96 | 99 | 102 | 104 | 99 | 110 | 112 | ||||||
| Other Assets Noncurrent | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Assets | 412 | 392 | 384 | 370 | 335 | 315 | 323 | 321 | 332 | 323 | 323 | 328 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 9 | 11 | 3 | 7 | 9 | 6 | 2 | 7 | 6 | 2 | 12 | 12 | ||||||
| Long Term Debt Current | 64 | - | 0 | 0 | 0 | 12 | 15 | 15 | - | - | 0 | - | ||||||
| Operating Lease Liability Current | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 6 | 3 | 2 | ||||||
| Accrued Liabilities Current | 40 | 32 | 33 | 30 | 25 | 20 | 28 | 24 | 23 | 28 | 24 | 19 | ||||||
| Other Liabilities Current | 5 | 4 | 5 | 3 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 190 | 119 | 110 | 116 | 95 | 95 | 100 | 91 | 75 | 100 | 95 | 87 | ||||||
| Long Term Debt | - | - | - | - | - | - | - | 216 | 230 | 230 | 191 | 190 | ||||||
| Long Term Debt Noncurrent | 189 | 221 | 220 | 219 | 219 | 218 | 217 | - | - | - | 191 | - | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 19 | 18 | ||||||
| Operating Lease Liability Noncurrent | 31 | 31 | 32 | 32 | 32 | 33 | 33 | 34 | 34 | 33 | 35 | 35 | ||||||
| Other Liabilities Noncurrent | 13 | 8 | 8 | 3 | 8 | 5 | 2 | 9 | 8 | 2 | 5 | 4 | ||||||
| Liabilities | 422 | 379 | 370 | 371 | 354 | 351 | 353 | 349 | 351 | 353 | 329 | 324 | ||||||
Stockholders Equity Deficit | ||||||||||||||||||
| Business Combination Contingent Consideration Liability Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 | 5 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | - | 0 | 0 | 3 | 0 | 2 | 3 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 690 | 682 | 685 | 682 | 664 | 646 | 642 | 638 | 632 | 642 | 610 | 608 | ||||||
| Retained Earnings Accumulated Deficit | -700 | -669 | -671 | -682 | -683 | -681 | -672 | -667 | -651 | -672 | -617 | -604 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | -10 | 13 | 14 | -1 | -19 | -35 | -30 | -28 | -19 | -30 | -7 | 4 | ||||||
| Liabilities And Stockholders Equity | 412 | 392 | 384 | 370 | 335 | 315 | 323 | 321 | 332 | 323 | 323 | 328 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | ||||||
| Common Stock Shares Issued | 174 | 173 | 166 | 166 | 161 | 156 | 149 | 149 | 149 | 149 | 138 | 138 | ||||||
| Shares Outstanding | 174 | 173 | 166 | 166 | 161 | 156 | 149 | 149 | 149 | 149 | 138 | 138 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialXeris Biopharma Holdings, Inc. (XERS) — SEC Financial Statements & Analysis
Xeris Biopharma Holdings, Inc. (XERS) is a pharmaceutical preparations company. Xeris Biopharma Holdings, Inc. trades on Nasdaq as: XERS. Xeris Biopharma Holdings, Inc. (XERS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Xeris Biopharma Holdings, Inc. carries a market cap of $1.37B, a P/E ratio of -79.74x, a P/B ratio of -140.62x, a P/S ratio of 4.08x, an enterprise value of $1.50B, and an EV/EBITDA multiple of 39.43x. On profitability, it posts a gross margin of 86.58%, an operating margin of 10.91%, a net margin of -5.12%, a Return on Equity (ROE) of 118.22%, a Return on Assets (ROA) of -4.60%, and a Return on Invested Capital (ROIC) of 27.57%. Per share, it reports EPS of $-0.10, diluted EPS of $-0.10, free cash flow per share of $0.33, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 17.01% year-over-year, net income growth of -66.33% year-over-year, and EPS growth of -68.93% year-over-year. On the balance sheet, it maintains a current ratio of 1.45x, a quick ratio of 0.95x, working capital of $85.19M, a debt-to-equity ratio of -43.32x, a debt ratio of 1.02, an interest coverage ratio of 1.30x, free cash flow of $56.61M (TTM), and net debt of $126.82M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.37B
- P/E TTM
- -79.74x
- EPS TTM
- $-0.10
- P/B TTM
- -140.62x
- ROE TTM
- 118.22%
- ROA TTM
- -4.60%
- Debt To Equity
- -43.32x
- Free Cash Flow TTM
- $56.61M
- Net Revenue TTM Growth 1Y
- 17.01%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Xeris Biopharma Holdings, Inc. in?
Xeris Biopharma Holdings, Inc. (XERS) operates in the Pharmaceutical Preparations industry.
What exchange does XERS trade on?
Xeris Biopharma Holdings, Inc. (XERS) trades on the Nasdaq.
When was Xeris Biopharma Holdings, Inc. (XERS)'s most recent SEC filing?
Xeris Biopharma Holdings, Inc. (XERS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is XERS's market cap?
Xeris Biopharma Holdings, Inc. (XERS) has a market capitalization of $1.37B as of 2026-06-30.
What is XERS's EPS (earnings per share)?
Xeris Biopharma Holdings, Inc. (XERS)'s trailing twelve month EPS is $-0.10 as of 2026-06-30.
What is XERS's ROE (return on equity)?
Xeris Biopharma Holdings, Inc. (XERS)'s trailing twelve month Return on Equity (ROE) is 118.22% as of 2026-06-30.
What is XERS's ROA (return on assets)?
Xeris Biopharma Holdings, Inc. (XERS)'s trailing twelve month Return on Assets (ROA) is -4.60% as of 2026-06-30.
What is XERS's ROIC (return on invested capital)?
Xeris Biopharma Holdings, Inc. (XERS)'s trailing twelve month Return on Invested Capital (ROIC) is 27.57% as of 2026-06-30.
What is XERS's EV/EBITDA?
Xeris Biopharma Holdings, Inc. (XERS)'s trailing twelve month EV/EBITDA is 39.43x as of 2026-06-30.